A novel inhaled PI3Kδ inhibitor, LAS194223 reduces allergen-induced airway inflammation in rat

M. Calbet, M. Lehner, E. Calama, A. Domenech, J. Cabedo, M. Dominguez, M. Erra, J. De Alba, N. Prats, M. Miralpeix (Sant Feliu del Llobregat, Spain)

Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis
Session: New drugs for asthma, COPD and pulmonary fibrosis
Session type: Oral Presentation
Number: 3410
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Calbet, M. Lehner, E. Calama, A. Domenech, J. Cabedo, M. Dominguez, M. Erra, J. De Alba, N. Prats, M. Miralpeix (Sant Feliu del Llobregat, Spain). A novel inhaled PI3Kδ inhibitor, LAS194223 reduces allergen-induced airway inflammation in rat. Eur Respir J 2014; 44: Suppl. 58, 3410

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
New inhaled JAK inhibitor LAS194046 inhibits allergen-induced airway inflammation in Brown Norway rats
Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis
Year: 2014

The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatics
Source: International Congress 2014 – Asthma and COPD management
Year: 2014

In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Year: 2014

In vitro profile of the new inhaled pan-JAK inhibitor LAS194046
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Year: 2014

Effect of roflumilast on airway remodeling in a murine model of chronic asthma
Source: International Congress 2015 – New models for treating airway diseases
Year: 2015


LATE-BREAKING ABSTRACT: Effects of a dual CysLT1/2 antagonist, ONO-6950, on allergen-induced airway responses in subjects with mild allergic asthma.
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014

Species comparison of interleukin-13 induced airway hyperreactivity as model for allergic asthma
Source: International Congress 2014 – Animal models in respiratory drug development
Year: 2014

LATE-BREAKING ABSTRACT: Attenuation of allergen-induced asthmatic responses by inhaled GATA-3 specific DNAzyme
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014

Inhibition of JAK/STAT pathway in airway epithelium as a potential targeted therapy of asthma
Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis
Year: 2014


Improved effects of aerosol-type fluticasone propionate/formoterol combination on residual asthmatic inflammation in distal airways of patients with moderate asthma
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


CRAC channel inhibition by RP3128 ameliorates airway hyper-reactivity in antigen sensitized mice and guinea pigs
Source: International Congress 2014 – Novel targets and drugs for asthma and COPD
Year: 2014

Clinical effectiveness of anti-IgE therapy in allergic severe asthma
Source: International Congress 2014 – Asthma and COPD management
Year: 2014

Improved effects of formoterol-budesonide combination on residual eosinophilic inflammation in asthmatic peripheral airway
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013


cPLA2alpha inhibitor ASB14780 suppresses airway MMP-9 production and improves respiratory function in cigarette-smoke induced model
Source: International Congress 2014 – Animal models in respiratory drug development
Year: 2014


AZD5069: Pharmacological profile of a CXCR2 antagonist in development for the treatment of respiratory disorders
Source: International Congress 2014 – Novel evidence relating to respiratory treatment development
Year: 2014

Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014

Bronchodilator effect of a novel inhaled dual PDE3/4 inhibitor, RPL554, in mild allergic asthma & rhinitis
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013


Effectively targeting small airways using controlled inhalation for peripheral corticosteroid deposition
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014


The effect of vitamin D therapy on airway reactivity and airway inflammation in asthmatic children
Source: Annual Congress 2013 –Preschool wheeze
Year: 2013

The effect of trehalose for the allergen-induced airway hyperresponsiveness and airway inflamation in mice
Source: Annual Congress 2013 –Cell biology and murine models of asthma and inflammation
Year: 2013